U.S., April 21 -- ClinicalTrials.gov registry received information related to the study (NCT07538193) titled 'Iparomlimab and Tuvonralimab Plus Chemotherapy Before Surgery for Stage III Lung Cancer' on March 16.
Brief Summary: Background: For patients with resectable stage III-N2b non-small cell lung cancer (NSCLC), optimal perioperative treatment strategies remain an area of active investigation. Iparomlimab and tuvonralimab (QL1706) is a novel bifunctional antibody combination targeting PD-1 and CTLA-4, designed to enhance anti-tumor immunity.
Objective: This phase II, single-arm, multicenter study aims to evaluate the efficacy and safety of neoadjuvant iparomlimab and tuvonralimab (QL1706) in combination with platinum-based chemotherap...